The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) versus placebo (PBO) + chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
 
Eric Raymond
No Relationships to Disclose
 
Richard Hubner
Consulting or Advisory Role - BeiGene; Boston Scientific; Ipsen; Novartis
Travel, Accommodations, Expenses - Roche
 
Evgeny Gotovkin
No Relationships to Disclose
 
Lucjan Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Paula Jimenez-Fonseca
Speakers' Bureau - BMS GmbH & Co. KG; Lilly
Other Relationship - IPSEN
 
Roberto Pazo-Cid
No Relationships to Disclose
 
Jianming Xu
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Aiyang Tao
No Relationships to Disclose
 
Lei Wang
Employment - BeiGene
 
Yanyan Peng
Employment - Beigene
Stock and Other Ownership Interests - Beigene
 
Liyun Li
Employment - BeiGene; Johnson & Johnson/Janssen (I)
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene; Johnson & Johnson/Janssen (I)
 
Harry H. Yoon
Consulting or Advisory Role - ALX ONCOLOGY; Astellas Scientific and Medical Affairs Inc; AstraZeneca; BeiGene; Bristol-Myers Squibb; LSK Biopharma; Macrogenics; Merck; Novartis; OncXerna Therapeutics; Zymeworks
Research Funding - Boston Biomedical (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly